Le Lézard
Classified in: Health
Subject: SVY

Microbiology Testing/Clinical Microbiology Market, 2023 - Improving Healthcare Infrastructure Across Emerging Countries


DUBLIN, Sept. 20, 2018 /PRNewswire/ --

The "Microbiology Testing/Clinical Microbiology Market by Application , Disease , Product , End User - Global Forecast to 2023" report has been added to ResearchAndMarkets.com's offering.

Research and Markets Logo

The global clinical microbiology market is expected to reach USD 4.95 billion by 2023 from USD 3.63 billion in 2018, growing at a CAGR of 6.4%.

The technological advancements in disease diagnostics, rising incidence of infectious diseases and growing outbreak of epidemics, and increased funding and public-private investments in the field of disease diagnosis are the key factors driving the growth of this market.

On the basis of products, the market is categorized into instruments (laboratory instruments and microbiology analyzers) and reagents (pathogen-specific kits and general reagents). The instruments segment is expected to account for the largest share of the global clinical microbiology market in 2018. Factors such as the significant adoption of conventional laboratory instruments among end users, technological advancements in the field of molecular techniques & proteomics (such as the integration of microfluidics with PCR and nanotechnology with qPCR techniques), and the ongoing trend of laboratory automation among clinical laboratories, are propelling growth in this segment.

The instruments product segment is further subsegmented into laboratory instruments (incubators, gram stainers, autoclave sterilizers, bacterial colony counters, microbial air samplers, blood culture counters, microbial culture systems, anaerobic culture systems, petri dish fillers, and other laboratory instruments) and microbiology analyzers (molecular diagnostic instruments, advanced microscopes, and mass spectrometers). The microbiology analyzers product segment is expected to grow at highest CAGR during the forecast period. This can be attributed to the increasing adoption of advanced analyzers for disease diagnosis by end users, and technological advancements in the field of molecular diagnostic instruments.

Similarly, the reagents product segment is further subsegmented into pathogen-specific kits and general reagents. The pathogen-specific kits segment is expected to grow at higher CAGR during the forecast period. The growth of this segment is attributed to factors such as the flexibility pathogen-specific kits offer to end users to optimize the reaction for better results and increasing patient preference across major countries for early and accurate disease diagnosis.

On the basis of disease area, the clinical microbiology market is segmented into respiratory diseases, bloodstream infections (BSIs), gastrointestinal (GI) diseases, sexually transmitted diseases (STDs), urinary tract infections (UTIs), periodontal diseases, and other diseases (including cardiovascular disease, central nervous system infections, connective tissue & joint diseases, and skin diseases). The respiratory disease segment is estimated to witness the highest growth during the forecast period, primarily due to as the large patient population suffering from respiratory diseases (coupled with the growing exposure to key risk factors such as pollution) and the increasing number of epidemic outbreaks of respiratory infections.

On the basis of end user, the clinical microbiology market is segmented into hospitals and diagnostic centers, custom lab service providers, and academic and research institutes. The custom lab service providers segment is estimated to witness the highest growth during the forecast period owing to the continuous outsourcing of drug testing procedures to laboratory service providers by pharmaceutical companies, procedural benefits offered by advanced molecular technology-based instruments (such as PCR and NGS) in drug discovery, increasing number of microbiology-based clinical trials, and the growing number of custom lab service providers across major markets.

Microbiology Testing/Clinical Microbiology Market

Geographically, this market is classified into North America, Europe, Asia Pacific, and RoW. In 2018, the global clinical microbiology market is expected to be dominated by North America. However, the Asia Pacific region is expected to witness the fastest growth during the forecast period owing to the government efforts to increase awareness related to genome-based infectious disease diagnosis; rising healthcare expenditure; increasing number of hospitals and clinical diagnostic laboratories in India and China; expanding research base across India, China, and Japan; and the increasing incidence of infectious diseases.

While the market is expected to grow at a steady rate in the next five years, factors such as reimbursement concerns and unfavorable regulatory scenario in some nations are expected to restrict market growth.

Product launches and enhancements are the key growth strategies adopted by major players to strengthen their position in the global microbiology testing/clinical microbiology market. In addition, strategies such as agreements, partnerships, and collaborations; acquisitions; and expansions were also adopted by several market players to remain competitive in the market.

Some of the key players operating in the global microbiology testing/clinical microbiology market

Key Topics Covered:

1 Introduction

2 Research Methodology

3 Executive Summary

4 Premium Insights

4.1 Microbiology Testing Market (2018-2023)
4.2 Microbiology Testing Market, By Application, 2018-2023 (USD Billion)
4.3 Clinical Microbiology Market (2018-2023)
4.4 Clinical Microbiology Products Market, By Region (2018)
4.5 Clinical Microbiology Market, By Disease Area, 2018 vs 2023 (USD Million)
4.6 Geographic Analysis: Clinical Microbiology Market, By End User, 2018 vs 2023 (USD Million)

5 Market Overview

5.1 Introduction
5.2 Market Dynamics
5.2.1 Drivers
5.2.1.1 Technological Advancements in Disease Diagnostics
5.2.1.2 Rising Incidence of Infectious Diseases and Growing Outbreaks of Epidemics
5.2.1.3 Increased Funding and Public-Private Investments
5.2.2 Restraints
5.2.2.1 Limited Reimbursement Policies for Microbiology Testing Procedures
5.2.2.2 Unfavorable Regulatory Scenario
5.2.3 Opportunities
5.2.3.1 Improving Healthcare Infrastructure Across Emerging Countries
5.2.4 Challenges
5.2.4.1 Operational Barriers Related to the Use of Diagnostic Tests
5.2.4.2 Bundled Sales of Microbiology Testing Products - A Key Challenge for Small and Emerging Reagent Manufacturers

6 Microbiology Testing Market, By Application

6.1 Introduction
6.2 Pharmaceutical Applications
6.3 Clinical Applications
6.4 Food Testing Applications
6.5 Energy Applications
6.6 Chemical & Material Manufacturing Applications
6.7 Environmental Applications

7 Clinical Microbiology Market, By Product

7.1 Introduction
7.2 Instruments
7.2.1 Laboratory Instruments
7.2.1.1 Incubators
7.2.1.2 Gram Stainers
7.2.1.3 Bacterial Colony Counters
7.2.1.4 Autoclave Sterilizers
7.2.1.5 Microbial Air Samplers
7.2.1.6 Anaerobic Culture Systems
7.2.1.7 Petri Dish Fillers
7.2.1.8 Blood Culture Systems
7.2.1.9 Microbial Culture Systems
7.2.1.10 Other Laboratory Instruments
7.2.2 Microbiology Analyzers
7.2.2.1 Molecular Diagnostic Instruments
7.2.2.2 Microscopes
7.2.2.3 Mass Spectrometers
7.3 Reagents
7.3.1 Pathogen-Specific Kits
7.3.2 General Reagents

8 Clinical Microbiology Market, By Disease Area

8.1 Introduction
8.2 Respiratory Diseases
8.3 Bloodstream Infections
8.4 Gastrointestinal Diseases
8.5 Sexually Transmitted Diseases
8.6 Urinary Tract Infections
8.7 Periodontal Diseases
8.8 Other Diseases

9 Clinical Microbiology Market, By End User

9.1 Introduction
9.2 Hospitals & Diagnostic Centers
9.3 Custom Lab Service Providers
9.4 Academic & Research Institutes

10 Microbiology Testing/Clinical Microbiology Market, By Region

10.1 Introduction
10.2 North America
10.2.1 US
10.2.2 Canada
10.3 Europe
10.3.1 Germany
10.3.2 UK
10.3.3 France
10.3.4 Rest of Europe
10.4 Asia Pacific
10.4.1 Japan
10.4.2 China
10.4.3 India
10.4.4 Rest of APAC
10.5 Rest of the World (RoW)
10.5.1 Latin America
10.5.2 Middle East and Africa

11 Competitive Landscape

11.1 Overview
11.2 Market Share Analysis
11.3 Competitive Scenario
11.3.1 Key Product Launches and Approvals (2014-2018)
11.3.2 Key Agreement, Partnerships, and Collaborations (2014-2018)
11.3.3 Key Acquisitions and Divestments (2014-2018)
11.3.4 Key Expansions (2014-2018)

12 Company Profiles

For more information about this report visit

https://www.researchandmarkets.com/research/s33z2m/microbiology?w=5

Media Contact:

Laura Wood, Senior Manager
[email protected]  

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets


These press releases may also interest you

at 17:00
MosquitoMate, Inc., a leader in innovative mosquito control solutions, today announced that the United States Environmental Protection Agency (EPA) has granted registration for its revolutionary new product named "WB1 Males." This new mosquito...

at 17:00
Leading family safety and location app Life360, has today announced the rollout of new safety features and enhancements through a triple-tier membership structure, offering a spectrum of benefits. With 2 million Aussies already benefiting from the...

at 16:55
The Registered Nurses' Association of Ontario (RNAO) is welcoming 17 new health organizations to its world-renowned Best Practice Spotlight Organization® (BPSO®) program. These organizations, spanning all health-care sectors, join RNAO in its mission...

at 16:54
Dr. Ryan M. Jouett, DDS, LVIM, FICOI has become one of only 25 Master Dentists in the world as a graduate of the Las Vegas Institute for Advanced Dental Studies in Las Vegas, NV....

at 16:48
Endo, Inc. ("Endo" or the "Company"), a newly formed entity, today announced that it has successfully completed the previously announced acquisition of substantially all of the assets of Endo International plc ("EIP"), as contemplated under EIP's...

at 16:45
Solventum announced today that it will release carve-out financial results for the first quarter 2024 before the market opens on May 9, 2024. The earnings press release and accompanying materials will be available on the company's website at...



News published on and distributed by: